Skip to main content

Advertisement

SpringerLink
Log in

Chemoprevention of Breast Cancer

Implications for Postmenopausal Women

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Estrogen administration is associated with reduction in perimenopausal symptoms and the risk for several conditions affecting postmenopausal women. As estrogen administration also increases the risk for breast cancer, a common dilemma facing many women and their physicians is whether to use estrogen replacement therapy (ERT), a selective estrogen receptor modulator (SERM) that antagonises estrogenic effects in breast tissue but retains some estrogen agonist properties in other organs, or neither.

For women with average to moderate risk of breast cancer and with perimenopausal symptoms, ERT may be the best short-term choice. For very high-risk women (>1% per year) with menopausal symptoms, alternatives to ERT might be offered and tried first. A diagnosis of ductal carcinoma in situ or invasive breast cancer within the last 2 to 5 years should be considered a relative contraindication for ERT unless the tumour was estrogen receptor negative.

High-risk women without menopausal symptoms are the best candidates for the only currently approved drug for breast cancer risk reduction, tamoxifen. Although the drug is approved for women with a 5-year risk of breast cancer ≥1.7% (0.34% per year), postmenopausal women most likely to experience a favourable benefit/risk ratio are those with a Gail estimated risk of >0.5% per year without a uterus or >1% per year if they retain their uterus. Tamoxifen should not be used in women with prior history of thromboembolic or precancerous uterine conditions. Tamoxifen is often used in Europe in conjunction with transdermal ERT in hysterectomised women without obvious loss of efficacy or increased risk of thromboembolism.

Raloxifene is a second generation SERM with estrogen-like agonist effects on bone but with less uterine estrogen agonist activity than tamoxifen. Raloxifene may have less potent breast antiestrogenic effects than tamoxifen, particularly in a moderate- to high-estrogen environment. Raloxifene is approved for use in reducing risk of osteoporosis, but not breast cancer. Whether it is as effective as tamoxifen in reducing breast cancer risk in postmenopausal women is the subject of a current trial.

All women regardless of breast cancer risk are advised to employ non-pharmacological risk reduction measures, including normalisation of body-weight, exercise, adequate calcium and vitamin D intake, and avoidance of smoking and alcohol.

The preventive options are best weighed during an individualised consultation where a woman’s menopausal symptoms and risk for breast cancer and other diseases can be examined, and the options for improving postmenopausal health can be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Table II
Table III
Table IV
Fig. 5
Fig. 6
Table V
Table VI
Fig. 7
Table VII

Similar content being viewed by others

References

  1. Landis SH, Murry T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8–31

    Article  PubMed  CAS  Google Scholar 

  2. Boone CW, Kelloff GJ. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention. J Cell Biochem Suppl 1993; 17: 37–48

    Article  Google Scholar 

  3. Kelloff G. Mechanistic considerations in chemopreventive drug development. J Cell Biochem Suppl 1994; 20: 1–24

    Article  PubMed  CAS  Google Scholar 

  4. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Linda Rosenthal foundation award lecture. Cancer Res 1988; 48: 246–53

    PubMed  CAS  Google Scholar 

  5. Clark G, Osborne C, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984; 2: 1102–9

    PubMed  CAS  Google Scholar 

  6. Chlebowski RT, Collyar DE, Somerfield MR, et al. American Society of Clinical Oncology technology assessment of breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999; 17: 1939–55

    PubMed  CAS  Google Scholar 

  7. Sato M, Glasebrook AL, Bryant HV. Raloxifene: a selective estrogen receptor modulator. J Bone Miner Metab 1995; 12(2 Suppl.): S9–S20

    Google Scholar 

  8. Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997; 177: 1458–64

    Article  PubMed  CAS  Google Scholar 

  9. Lindsey R, Bush TL, Grady D, et al. Therapeutic controversy-estrogen replacement in menopause. J Clin Endocrinol Metab 1996; 81: 3829–38

    Article  Google Scholar 

  10. Epstein S, Goodman GR. Improved strategies for diagnosis and treatment of osteoporosis. Menopause 1999; 6: 242–50

    Article  PubMed  CAS  Google Scholar 

  11. Kado DM, Browner WS, Palermo L, et al. Vertebrae fractures and mortality in older women: a prospective study of osteoporosis fracture research group. Arch Intern Med J 1999; 159: 1215–20

    Article  CAS  Google Scholar 

  12. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–7

    PubMed  CAS  Google Scholar 

  13. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75–8

    Article  PubMed  CAS  Google Scholar 

  14. PEPI trial group. Effects of estrogen or estrogen/progesterone regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199–208

    Article  Google Scholar 

  15. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75

    Article  PubMed  CAS  Google Scholar 

  16. Birge SJ. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? J Am Geriatr Soc 1996; 44: 865–70

    PubMed  CAS  Google Scholar 

  17. Callee EE, Miracle-McMahell HL, Thun MJ. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995; 87: 517–23

    Article  Google Scholar 

  18. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997; 127: 913–80

    Google Scholar 

  19. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997; 277: 1140–7

    Article  PubMed  CAS  Google Scholar 

  20. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 736–46

    Article  PubMed  CAS  Google Scholar 

  21. Magaziner J, Lydick E, Hawkes W. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health 1997; 87: 1630–6

    Article  PubMed  CAS  Google Scholar 

  22. LeBlanc ES, Janowsky J, Chan BKS, et al. Hormone replacement therapy and cognition. JAMA 2001; 285: 1489–99

    Article  PubMed  CAS  Google Scholar 

  23. Grady D, Wenger NK, Harrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Intern Med 2000; 132: 689–96

    PubMed  CAS  Google Scholar 

  24. Women’s health initiative study group. Design of the women’s health initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61–109

    Article  Google Scholar 

  25. Jacobs HS. Postmenopausal hormone replacement therapy and breast cancer. Medscape Womens Health 2000; 5: E2

    PubMed  CAS  Google Scholar 

  26. Gail MH, Briton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879–86

    Article  PubMed  CAS  Google Scholar 

  27. Bondy ML, Lustbader ED, Hababi S, et al. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994; 86: 620–5

    Article  PubMed  CAS  Google Scholar 

  28. Benichou J, Gail MH, Mulvill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 1996; 14: 103–10

    PubMed  CAS  Google Scholar 

  29. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999; 91: 1541–8

    Article  PubMed  CAS  Google Scholar 

  30. Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000; 92: 1217–27

    Article  PubMed  CAS  Google Scholar 

  31. Fabian CJ. Breast cancer chemoprevention: beyond tamoxifen. Breast Cancer Res 2001; 3: 99–103

    Article  PubMed  CAS  Google Scholar 

  32. Newton KM, LaCroix AZ, Leveille SG, et al. Women’s beliefs and decisions about hormone replacement therapy. J Womens Health 1997; 6: 459–65

    Article  PubMed  CAS  Google Scholar 

  33. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 1829–46

    Article  PubMed  CAS  Google Scholar 

  34. Fabian CJ, Kimler BF, Elledge RM. Models for early chemoprevention trials in breast cancer. Hematol Oncol Clin North Am 1998; 12: 993–1017

    Article  PubMed  CAS  Google Scholar 

  35. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975; 55: 231–73

    PubMed  CAS  Google Scholar 

  36. Kelloff GJ, Boone CW, Steele VE, et al. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res 1994; 54(7 Suppl.): 2015S–24

    PubMed  CAS  Google Scholar 

  37. Kelloff GJ, Boone CW, Crowell JA, et al. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem 1996; 25: 1–14

    CAS  Google Scholar 

  38. Fabian CJ, Kimler BF. Chemoprevention for high risk women: Tamoxifen and beyond. Breast J 2001; 7: 311–20

    Article  PubMed  CAS  Google Scholar 

  39. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141–96

    Article  PubMed  CAS  Google Scholar 

  40. Widschwendter M, Berger J, Hermann M, et al. Methylation and silencing of the retinoic acid receptor-B2 gene in breast cancer. J Natl Cancer Inst 2000; 92: 826–32

    Article  PubMed  CAS  Google Scholar 

  41. Baylin SB, Makos M, Wu J, et al. Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression. Cancer Cells 1991; 3: 383–90

    PubMed  CAS  Google Scholar 

  42. Ottaviano YL, Issa JP, Parl FF, et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994; 54: 2552–5

    PubMed  CAS  Google Scholar 

  43. Mommers EC, van Diest PJ, Leonhart AM, et al. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast. Human Pathol 1998; 29: 1539–45

    Article  CAS  Google Scholar 

  44. Mommers EC, van Diest PJ, Leonhart AM, et al. Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res Treat 1999; 58: 163–9

    Article  PubMed  CAS  Google Scholar 

  45. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941–53

    PubMed  CAS  Google Scholar 

  46. Fregene TA, Kellogg CM, Pienta KJ. Microvessel quantification as a measure of angiogenic activity in benign breast tissue lesions: a marker for precancerous disease? Int J Oncol 1994; 4: 1999–2002

    Google Scholar 

  47. Koukoulis GK, Vertanen I, Korhonen M, et al. Immunohisto-chemical localization of integrins in the normal, hyperlastic and neoplastic breast: correlations with their functions as receptors and cell adhesion molecules. Am J Pathol 1991; 139: 787–99

    PubMed  CAS  Google Scholar 

  48. Simpson JF, Page DL. Altered expression of a structural protein (fodrin) within epithelial proliferation disease of the breast. Am J Pathol 1992; 141: 285–9

    PubMed  CAS  Google Scholar 

  49. Kelloff GJ, Boone CW, Crowell JA, et al. Development of breast cancer chemopreventive drugs. Breast J 1995; 5: 271–83

    Article  Google Scholar 

  50. O’Connell P, Pekkel V, Fuqua SA, et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998; 90: 697–703

    Article  PubMed  Google Scholar 

  51. Stoll BA. Premalignant breast lesions: role for biological markers in predicting progression to cancer. Eur J Cancer 1999; 35: 693–7

    Article  PubMed  CAS  Google Scholar 

  52. Boone CW, Kelloff GJ, Freidman LS. Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution and its relationship to mechanisms of chemopreventive drug action. J Cell Biochem 1993; 17G: 14–25

    Article  CAS  Google Scholar 

  53. Modan B, Lubin F, Alfandary E, et al. Breast cancer following benign breast disease: a nationwide study [abstract]. Breast Cancer Res Treat 1997; 46: 45

    Google Scholar 

  54. Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer 1990; 66: 1326–35

    Article  PubMed  CAS  Google Scholar 

  55. Page DL, Kidd TE, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer by more extensive disease. Hum Pathol 1991; 22: 1232–9

    Article  PubMed  CAS  Google Scholar 

  56. Haagensen CD. Lobular neoplasia (lobular carcinoma in situ). In: Haagensen CD, editor. Diseases of the breast. 3rd ed. Philadelphia: W.B. Saunders, 1986: 192–241

    Google Scholar 

  57. Tavassoli FA, Norris HJ. A comparison of the results of long-term followup for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 1990; 65: 518–29

    Article  PubMed  CAS  Google Scholar 

  58. Tavassoli FA, Man Y. Morphofunctional features of intraductal hyperplasia, atypical intraductal hyperplasia, and various grades of intraductal carcinoma. Breast J 1995; 1: 155–62

    Article  Google Scholar 

  59. Nielsen M, Thomsen JL, Primdahl S, et al. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987; 56: 814–9

    Article  PubMed  CAS  Google Scholar 

  60. Nielsen M, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy. Cancer 1984; 54: 612–5

    Article  PubMed  CAS  Google Scholar 

  61. Nielsen M. Autopsy studies of the occurrence of cancerous, atypical and benign epithelial lesions in the female breast. APMIS Suppl 1989; 10: 1–56

    PubMed  CAS  Google Scholar 

  62. Bhathal PS, Brown RW, Lesueur GC, et al. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 1985; 51: 271–8

    Article  PubMed  CAS  Google Scholar 

  63. Khan SA. Estrogen and progesterone receptors in benign breast epithelium. Breast J 1995; 1: 251–61

    Article  Google Scholar 

  64. Khan SA, Sachdeva A, Naim S, et al. The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. Cancer Epidemiol Biomarkers Prev 1999; 25: 867–72

    Google Scholar 

  65. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001; 8: 47–61

    Article  PubMed  CAS  Google Scholar 

  66. Clarke RB, Howell A, Potten CS, et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997; 57: 4987–91

    PubMed  CAS  Google Scholar 

  67. Tsutsumi Y, Naber SP, DeLellis RA, et al. Neu-oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. Hum Pathol 1990; 21: 750–8

    Article  PubMed  CAS  Google Scholar 

  68. van Agthoven T, Timmermans M, Foekens JA, et al. Differential expression of estrogen, progesterone and epidermal growth factor receptor in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol 1994; 144: 1238–46

    PubMed  Google Scholar 

  69. Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 1998; 3: 49–61

    Article  PubMed  CAS  Google Scholar 

  70. Russo J, Ao X, Grill C, et al. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 1999; 53: 217–27

    Article  PubMed  CAS  Google Scholar 

  71. Russo IH, Russo J. Hormonal approach to breast cancer prevention. J Cell Biochem 2000; 77(S34): 1–6

    Article  Google Scholar 

  72. Peterson OW, Hoyer PE, vanDeurs B. Frequency and distribution of estrogen-receptor positive cells in normal non-lactating human breast tissue. Cancer Res 1987; 47: 5748–51

    Google Scholar 

  73. Ricketts D, Turnbull L, Ryall G, et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991; 51: 1817–22

    PubMed  CAS  Google Scholar 

  74. Markopoulos C, Berger U, Wilson P, et al. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. BMJ 1988; 296: 1349–51

    Article  PubMed  CAS  Google Scholar 

  75. Soderqvist G, von Schoultz B, Tani E, et al. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obst Gynecol 1993; 168: 874–9

    CAS  Google Scholar 

  76. Battersby S, Robertson BJ, Anderson TJ, et al. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast. Br J Cancer 1992; 4: 601–7

    Article  Google Scholar 

  77. Dickson RB, Kasid A, Huff KK, et al. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 1987; 84: 837–41

    Article  PubMed  CAS  Google Scholar 

  78. Dickson R, Lippman M. Autocrine and paracrine growth factors in the normal and the neoplastic breast. In: Harris J, Lippman M, Monrow M, Hellman S, editors. Diseases of the breast. Philadelphia: Lippincott-Raven, 1996: 272–83

    Google Scholar 

  79. Parham DM, Jankowski J. Transforming growth factor α in epithelial proliferative diseases of the breast. J Clin Pathol 1992; 45: 517–20

    Article  PubMed  CAS  Google Scholar 

  80. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472–89

    Article  PubMed  CAS  Google Scholar 

  81. Hyder SM, Nawaz Z, Chiappetta C, et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000; 60: 3183–90

    PubMed  CAS  Google Scholar 

  82. Roger P, Daures JP, Maudelonde T, et al. Dissociated over-expression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. Hum Pathol 2000; 31: 593–600

    Article  PubMed  CAS  Google Scholar 

  83. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphirequlin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997; 70: 722–6

    Article  PubMed  CAS  Google Scholar 

  84. De Leon DD, Terry C, Asmerom Y, et al. Insulin-like growth factor II modulates the routing of cathepsin D in MCF-7 breast cancer cells. Endocrinology 1996; 137: 1851–9

    Article  PubMed  Google Scholar 

  85. Dati C, Antoniotti S, Taverna D, et al. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990; 5: 1001–6

    PubMed  CAS  Google Scholar 

  86. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal adult and fetal tissues. Oncogene 1990; 5: 953–62

    PubMed  CAS  Google Scholar 

  87. Balsari A, Casalini P, Tagliabue E, et al. Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle. Am J Pathol 1999; 155: 1543–7

    Article  PubMed  CAS  Google Scholar 

  88. Pasqualini JR. Recent developments of the biological role of progestins in human breast cancer. J Womens Cancer 2000; 2: 135–43

    Google Scholar 

  89. Druckmann R. Mammary effects of progestins. J Womens Cancer 2000; 2: 85–92

    Google Scholar 

  90. Shrestha P, Yamada K, Wada T, et al. Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer. Virchows Arch A Pathol Anat Histopathol 1992; 421: 193–202

    Article  PubMed  CAS  Google Scholar 

  91. Mukku V, Sancel GM. Regulation of epidermal growth factor receptor by estrogen. J Biol Chem 1985; 260: 9820–4

    PubMed  CAS  Google Scholar 

  92. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemo-theraputic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902–7

    PubMed  CAS  Google Scholar 

  93. Gamroudi F, Cullen KJ. Insulin-like growth factors in breast cancer. J Womens Cancer 2000; 2: 41–52

    Google Scholar 

  94. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10: 382–93

    Article  PubMed  CAS  Google Scholar 

  95. Balana ME, Lupu R, Labriola L, et al. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. Oncogene 1999; 18: 6370–9

    Article  PubMed  CAS  Google Scholar 

  96. Musgrove EA, Lee CS, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991; 11: 5032–43

    PubMed  CAS  Google Scholar 

  97. Papa V, Reese CC, Brunetti A, et al. Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinoma cells. Cancer Res 1990; 50: 7858–62

    PubMed  CAS  Google Scholar 

  98. Sabourin JC, Martin A, Barvch J, et al. BCL-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 1994; 59: 1–6

    Article  PubMed  CAS  Google Scholar 

  99. Kandouz M, Siromachkova M, Jacob D, et al. Antagonism between estradiol and progestin on bcl-2 expression in breast cancer cells. Int J Cancer 1996; 68: 120–5

    Article  PubMed  CAS  Google Scholar 

  100. Potten CS, Watson RJ, Williams GT, et al. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988; 58: 163–70

    Article  PubMed  CAS  Google Scholar 

  101. Yue W, Santner SJ, Masamura S, et al. Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res Treat 1998; 49(1 Suppl.): S1–7; discussion S33-7

    Article  PubMed  CAS  Google Scholar 

  102. Vermeulen A, Deslypere JP, Paridaens R, et al. Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986; 22: 515–25

    Article  PubMed  CAS  Google Scholar 

  103. Pasqualini JR, Chetrite G, Nguyen BL, et al. Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol 1995; 53: 407–12

    Article  PubMed  CAS  Google Scholar 

  104. Pasqualini JR, Cortes-Prieto J, Chetrite G, et al. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 1997; 70: 639–43

    Article  PubMed  CAS  Google Scholar 

  105. James VH, McNeill JM, Lai LC, et al. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 1987; 50: 269–79

    Article  PubMed  CAS  Google Scholar 

  106. Reed MJ, Topping L, Coldham A, et al. Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. J Steroid Biochem Mol Biol 1993; 44: 589–96

    Article  PubMed  CAS  Google Scholar 

  107. Zhao Y, Agarwal V, Mendelson C, et al. Estrogen synthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP; leading to activation of promoter II CYP 19 (aromatase) gene. Endocrinol 1996; 137: 5739–42

    Article  CAS  Google Scholar 

  108. Santen RJ, Yue W, Naftolin F, et al. The potential of aromatase inhibitors in breast cancer prevention. Endocr Relat Cancer 1999; 6: 235–43

    Article  PubMed  CAS  Google Scholar 

  109. Visscher DW, Padiyar N, Long D, et al. Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions. Breast J 1998; 4: 447–51

    Article  Google Scholar 

  110. Khan SA, Rogers AM, Obanda JA, et al. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994; 54: 993–7

    PubMed  CAS  Google Scholar 

  111. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast cancers. Breast Cancer Res Treat 1999; 53: 167–76

    Article  PubMed  CAS  Google Scholar 

  112. Scambia G, Benedetti Panici P, Ferrandina G, et al. Cathepsin D and epidermal growth factor in human breast cyst fluid. Br J Cancer 1991; 64: 965–7

    Article  PubMed  CAS  Google Scholar 

  113. Monteagudo C, Merino MJ, San-Juan J, et al. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 1990; 136: 585–92

    PubMed  CAS  Google Scholar 

  114. Stark A, Hulka BS, Joens S, et al. Her-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000; 8: 267–74

    Google Scholar 

  115. Stoica A, Saceda M, Fakhro A, et al. Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. J Cell Biochem 2000; 76: 605–14

    Article  PubMed  CAS  Google Scholar 

  116. Shoker BS, Jarvis C, Clarke RB, et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999; 155: 1811–5

    Article  PubMed  CAS  Google Scholar 

  117. Fuqua SA, Wiltschke C, Zhang QX, et al. A hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res 2000; 60: 4026–9

    PubMed  CAS  Google Scholar 

  118. Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996; 81: 1460–4

    Article  PubMed  CAS  Google Scholar 

  119. van Landeghem AA, Poortman J, Nabuurs M, et al. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985; 45: 2900–6

    PubMed  Google Scholar 

  120. Kato S, Endoh H, Yoshikazu M, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270: 1491–4

    Article  PubMed  CAS  Google Scholar 

  121. Bunone G, Briand PA, Miksicek RJ, et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15: 2174–83

    PubMed  CAS  Google Scholar 

  122. Taketo MM. Cyclooxygenase-2 inhibitors in tumorogenesis, Part I. J Natl Cancer Inst 1998; 90: 1529–36

    Article  PubMed  CAS  Google Scholar 

  123. Hwang D, Scottard D, Byrne J, et al. Expression of cyclo-oxygenase-1 and cyclo-oxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455–60

    Article  PubMed  CAS  Google Scholar 

  124. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Exp Opin Invest Drugs 1999; 8: 1623–38

    Article  CAS  Google Scholar 

  125. Hazan RB, Norton L. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 1998; 273: 9078–84

    Article  PubMed  CAS  Google Scholar 

  126. Lotem J, Peled-Kamar M, Groner Y, et al. Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines. Proc Natl Acad Sci USA 1996; 93: 9166–71

    Article  PubMed  CAS  Google Scholar 

  127. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–31

    Article  PubMed  CAS  Google Scholar 

  128. Zindy F, Eischen CM, Randle DH, et al. Myc signalling via the ARF tumor suppressor regulates p53 dependent apoptosis and immortalization. Genes Dev 1998; 12: 2424–33

    Article  PubMed  CAS  Google Scholar 

  129. Allan DJ, Howell A, Roberts SA, et al. Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J Pathol 1992; 167: 25–32

    Article  PubMed  CAS  Google Scholar 

  130. Starcevic SL, Elferink C, Novak RF. Progressive resistance to apoptosis in a cell lineage model of human proliferative breast disease. J Natl Cancer Inst 2001; 93: 776–82

    Article  PubMed  CAS  Google Scholar 

  131. Widschwendter M, Berger J, Daxewnbichler G, et al. Loss of retinoic acid receptor B expression in breast cancer and normal adjacent tissue but not in normal tissue distinct from the cancer. Cancer Res 1997; 57: 4158–61

    PubMed  CAS  Google Scholar 

  132. Huschtscha LI, Noble JR, Neumann AA, et al. Loss of p16INK4 expression of methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res 1998; 58: 3508–12

    PubMed  CAS  Google Scholar 

  133. Gobbi H, DuPont WD, Simpson JF, et al. Transforming growth factor-B and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999; 91: 2096–101

    Article  PubMed  CAS  Google Scholar 

  134. Hankins GR, De Souza AT, Bentley RC, et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996; 12: 2003–9

    PubMed  CAS  Google Scholar 

  135. Khan SA, Rogers MA, Khurana KK, et al. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998; 90: 37–42

    Article  PubMed  CAS  Google Scholar 

  136. Ferguson AT, Lapidus RG, Baylin SB, et al. Demethylation of the estrogen receptor gene in estrogen receptor: negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 1995; 55: 2279–83

    PubMed  CAS  Google Scholar 

  137. Wikstrand CJ, McLendon RE, Friedman AH, et al. Cell surface localization and density of the tumor associated variant of the epidermal growth factor receptor, EGFR VIII. Cancer Res 1997; 57: 4130–40

    PubMed  CAS  Google Scholar 

  138. Tang CK, Gong XQ, Moscatello DK, et al. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000; 60: 3081–7

    PubMed  CAS  Google Scholar 

  139. Moscatello DK, Holgado-Madrugra M, Emlet DR. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998; 273: 200–6

    Article  PubMed  CAS  Google Scholar 

  140. Berns EM, Klijn JG, van Staveren IL, et al. A sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 1992; 52: 1036–9

    PubMed  CAS  Google Scholar 

  141. Papa V, Gliozzo B, Clark GM, et al. Insulin-like growth factor-1 receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993; 53: 3736–40

    PubMed  CAS  Google Scholar 

  142. Resnicoff M, Abraham D, Yutanawiboonchai W, et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995; 55: 2463–9

    PubMed  CAS  Google Scholar 

  143. Pietrzkowski Z, Lammers R, Carpenter G, et al. Constitutive expression of insulin-like growth factor I and insulin-like growth factor I receptor abrogates all requirements for exogenous growth factors. Cell Growth Diff 1992; 3: 199–205

    PubMed  CAS  Google Scholar 

  144. Allred DC, Hilsenbeck SG. Biomarkers in benign breast disease: risk factors for breast cancer. J Natl Cancer Inst 1998; 90: 1247–8

    Article  PubMed  CAS  Google Scholar 

  145. Barbareschi M, Leonardi E, Mauri FA, et al. p53 and c-erbB-2 protein expression in breast carcinomas: an immunohisto-chemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992; 98: 408–18

    PubMed  CAS  Google Scholar 

  146. Peach K, Webb P, Kuïper GG, et al. Differential ligand activation of estrogen receptors ER-α and ER-β at AP-1 sites. Science 1997; 277: 1508–10

    Article  Google Scholar 

  147. Leygue E, Dotzlaw H, Watson PH, et al. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 1998; 58: 3197–201

    PubMed  CAS  Google Scholar 

  148. Petrangeli E, Lubrano C, Ravenna L, et al. Gene methylation of oestrogen and epidermal growth factor receptors in neoplastic and perineoplastic breast tissues. Br J Cancer 1995; 72: 973–5

    Article  PubMed  CAS  Google Scholar 

  149. Shibata H, Spencer TE, Onate SA, et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 1997; 52: 141–65

    PubMed  CAS  Google Scholar 

  150. Umayahara Y, Kawamori R, Watada H, et al. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994; 269: 16433–42

    PubMed  CAS  Google Scholar 

  151. Watanabe T, Inoue S, Ogawa S, et al. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 1997; 236: 140–5

    Article  PubMed  CAS  Google Scholar 

  152. Cowley SM, Hoare S, Mosselman S, et al. Estrogen receptors a and β form heterodimers on DNA. J Biol Chem 1997; 22: 19858–62

    Article  Google Scholar 

  153. Fuqua SA, Russo J, Shackney SE, et al. Estrogen, estrogen receptors and selective estrogen receptor modulators in human breast cancer. J Womens Cancer 2000; 2: 21–32

    Google Scholar 

  154. McKenna N, Lanz R, O’Malley B. Nuclear receptor co-regulators: cellular and molecular biology. Endocr Rev 1999; 20: 321–44

    Article  PubMed  CAS  Google Scholar 

  155. MacGregor-Schafer J, Liu H, Bentrem DJ, et al. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 2000; 60: 5097–105

    PubMed  CAS  Google Scholar 

  156. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000; 18: 3172–86

    PubMed  CAS  Google Scholar 

  157. Osborne CK, Yochmowitz MG, Knight WA 3rd, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46(12 Suppl.): 2884–8

    Article  PubMed  CAS  Google Scholar 

  158. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–59

    Article  Google Scholar 

  159. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998; 90: 814–23

    Article  PubMed  CAS  Google Scholar 

  160. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93

    Article  PubMed  CAS  Google Scholar 

  161. Cauley JA, Lucas FL, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 1999; 130: 270–7

    PubMed  CAS  Google Scholar 

  162. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestrins, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17–35

    PubMed  CAS  Google Scholar 

  163. Parazzini F, Braga C, La Vecchia C, et al. Hysterectomy, oophorectomy and premenopause, and risk of breast cancer. Obstet Gynecol 1997; 90: 453–65

    Article  PubMed  CAS  Google Scholar 

  164. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 1475–9

    Article  PubMed  CAS  Google Scholar 

  165. Davis DL, Telang NT, Osborne MP, et al. Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer. Environ Health Perspect 1997; 105(Suppl. 3): 571–6

    PubMed  CAS  Google Scholar 

  166. Anderson E, Clarke RB, Howell A. Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 1998; 3: 23–35

    Article  PubMed  CAS  Google Scholar 

  167. Nicholson RI, McClelland RA, Robertson JF, et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999; 6: 373–87

    Article  PubMed  CAS  Google Scholar 

  168. Foster JS, Wimalasena J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 1996; 10: 488–98

    Article  PubMed  CAS  Google Scholar 

  169. Matsuda S, Kadowaki Y, Ichino M, et al. 17 beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product. Proc Natl Acad Sci USA 1993; 90: 10803–7

    Article  PubMed  CAS  Google Scholar 

  170. Migliaccio A, Pagano M, Auricchio F. Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene 1993; 8: 2183–91

    PubMed  CAS  Google Scholar 

  171. Reed JC. Bcl-2 family proteins and the hormonal control of cell life and death in normalcy and neoplasia. Vitam Horm 1997; 53: 99–138

    Article  PubMed  CAS  Google Scholar 

  172. McCloskey DE, Armstrong DK, Jackisch C, et al. Programed cell death in human breast cancer cells. Recent Prog Horm Res 1996; 51: 493–508

    PubMed  CAS  Google Scholar 

  173. Long BJ, Lu Q, Brodie A. Expression and regulation of vascular endothelial growth factor in human breast cancer cells [abstract]. Proc Am Assoc Cancer Res 1997; 38: 572

    Google Scholar 

  174. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139–47

    Article  PubMed  CAS  Google Scholar 

  175. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 1993; 259: 633–8

    Article  PubMed  CAS  Google Scholar 

  176. Lydon JP, Gouqing G, Kittrell FS, et al. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res 1999; 59: 4276–84

    PubMed  CAS  Google Scholar 

  177. Gertig DM, Stillman IE, Byrne C, et al. Association of age and reproductive factors with benign breast tissue composition. Cancer Epidemiol Biomarkers Prev 1999; 8: 873–9

    PubMed  CAS  Google Scholar 

  178. Yue W, Wang JP, Hamilton CJ, et al. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 1998; 58: 927–32

    PubMed  CAS  Google Scholar 

  179. Jacquemier JD, Rolland PH, Vague D, et al. Relationships between steroid receptor and epithelial cell proliferation in benign fibrocystic disease of the breast. Cancer 1982; 49: 2534–6

    Article  PubMed  CAS  Google Scholar 

  180. van Landeghem AA, Poortman J, Nabuurs M, et al. Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue. Cancer Res 1985; 45: 2907–12

    PubMed  Google Scholar 

  181. Wickerham DL, Costantino J, Fisher B, et al. Average annual rates of invasive and non-invasive breast cancer by history of LCIS and atypical hyperplasia for participants in the BCPT [abstract]. Proc Am Soc Clin Oncol 1999; 18: 87

    Google Scholar 

  182. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997; 6: 297–301

    PubMed  CAS  Google Scholar 

  183. Dupont WD, Page DC. Breast cancer risk associated with proliferative disease, age at first live birth and a family history of breast cancer. Am J Epidemiol 1987; 125: 769–79

    PubMed  CAS  Google Scholar 

  184. Boyd NF, Lockwood GA, Bying JW, et al. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prevent 1998; 7: 1133–44

    CAS  Google Scholar 

  185. Colditz GA, Rosner BA, Splizer FE. Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 1996; 88: 365–71

    Article  PubMed  CAS  Google Scholar 

  186. O’Connell DL, Hulka BS, Chambless LE, et al. Cigarette smoking, alcohol consumption and breast cancer risk. J Natl Cancer Inst 1987; 78: 229–34

    PubMed  Google Scholar 

  187. Holmberg L, Baron JA, Byers T, et al. Alcohol intake and breast cancer risk: effect of exposure from 15 years of age. Cancer Epidemiol Biomark Prevent 1995; 4: 844–7

    Google Scholar 

  188. Madigan PM, Ziegler RG, Benichou J, et al. Proportion of breast cancer cases in the United States explained by well established risk factors. J Natl Cancer Inst 1987; 87: 1681–5

    Article  Google Scholar 

  189. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995; 87: 1297–302

    Article  PubMed  CAS  Google Scholar 

  190. Sellers TA, Kushi LH, Potter JD, et al. Effect of family history, body-fat distribution and reproductive factors on the risk of postmenopausal breast cancer. N Engl J Med 1992; 326: 1323–9

    Article  PubMed  CAS  Google Scholar 

  191. Hunter DJ, Willet WC. Diet, body size and breast cancer. Epidemiol Rev 1993; 15: 110–32

    PubMed  CAS  Google Scholar 

  192. Longnecker MP. Alcoholic beverage consumption in relation to risk of breast cancer: meta-analysis and review. Cancer Causes Control 1994; 5: 73–82

    Article  PubMed  CAS  Google Scholar 

  193. Thiessen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80–101

    Google Scholar 

  194. Kosary CL, Ries LAG, Miller BA, Hankey BF, Karras A, Edwards BK, editors. Breast cancer trends, incidence, mortality and survival. In: SEER Cancer Statistics Review 1973-1992 tables and graphs. Bethesda (MD): National Cancer Institute, 1995: 121–41

  195. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001; 93: 358–66

    Article  PubMed  CAS  Google Scholar 

  196. Frykberg ER, Bland KI. Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer 1994; 74: 350–61

    Article  PubMed  CAS  Google Scholar 

  197. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16: 441–52

    PubMed  CAS  Google Scholar 

  198. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Cancer 1994; 73: 643–51

    Article  PubMed  CAS  Google Scholar 

  199. Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997; 89: 227–38

    Article  PubMed  CAS  Google Scholar 

  200. Euhus DM: Understanding mathematical models for breast cancer risk assessment and counseling. Breast J 2001; 7: 224–32

    Article  PubMed  CAS  Google Scholar 

  201. Mezzetti M, La Vecchia C, Decarli A, et al. Population attributable risk for breast cancer: diet, nutrition, and physical exercise. J Natl Cancer Inst 1998; 90: 389–94

    Article  PubMed  CAS  Google Scholar 

  202. Freedman LS, Schatxkin A, Shiffman MH. Statistical validation of intermediate markers of precancer for use as endpoints in chemoprevention trials. J Cellular Biochem 1992; 16Suppl. G: 27–32

    Article  Google Scholar 

  203. Wrensch M, Petrakis NL, King EB, et al. Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy. Am J Epidemiol 1993; 137: 829–33

    PubMed  CAS  Google Scholar 

  204. Sauter ER, Ross E, Daly M, et al. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 1997; 76: 494–501

    Article  PubMed  CAS  Google Scholar 

  205. Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000; 92: 1054–64

    Article  PubMed  CAS  Google Scholar 

  206. Remvikos Y, Gerbault-Seureau M, Magdelenat H, et al. Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis. Breast Cancer Res Treat 1992; 23: 43–9

    Article  PubMed  CAS  Google Scholar 

  207. Dowsett M, Dixon JM, Horgan K, et al. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res 2000; 6: 2260–7

    PubMed  CAS  Google Scholar 

  208. Boeddinghaus IM, Dowsett M, Smith IE, et al. Neoadjuvant arimidex or tamoxifen alone or combined for breast cancer (impact): PgR related reductions in proliferation marker Ki67 [abstract]. Proc Am Soc Clin Oncol 2000; 19: 94

    Google Scholar 

  209. Wellings SR, Wolfe J. Correlative studies of the histological and radiographic appearance of the breast parenchyma. Radiology 1978; 129: 299–306

    PubMed  CAS  Google Scholar 

  210. Boyd NF, Fishell E, Jong R, et al. Mammographic densities as a criterion for entry to a clinical trial of breast cancer prevention. Br J Cancer 1995; 72: 476–9

    Article  PubMed  CAS  Google Scholar 

  211. Boyd NF, Greenberg C, Lockwood G, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. J Natl Cancer Inst 1997; 89: 488–96

    Article  PubMed  CAS  Google Scholar 

  212. Pollak M, Costantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990; 82: 1693–7

    Article  PubMed  CAS  Google Scholar 

  213. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density: postmenopausal estrogen/progestin interventions (PEPI) investigators. Ann Intern Med 1999; 130: 262–9

    PubMed  CAS  Google Scholar 

  214. Atkinson C, Warren R, Bingham SA, et al. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomark Prev 1999; 8: 863–6

    CAS  Google Scholar 

  215. Bruning PF, Van Doorn J, Bonfrer JM, et al. Insulin-like growth-factor-binding protein 3 is decreased in early stage operable pre-menopausal breast cancer. Int J Cancer 1995; 28: 266–70

    Article  Google Scholar 

  216. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 9: 1393–6

    Article  Google Scholar 

  217. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age and menopause status. J Natl Cancer Inst 1995; 87: 1622–9

    Article  PubMed  CAS  Google Scholar 

  218. Byrne C, Colditz GA, Willet WC, et al. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000; 60: 3744–8

    PubMed  CAS  Google Scholar 

  219. Brisson J, Brisson B, Cote G, et al. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000; 9: 911–5

    PubMed  CAS  Google Scholar 

  220. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women’s health study. JAMA 1999; 281: 2091–7

    Article  PubMed  CAS  Google Scholar 

  221. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485–91

    Article  PubMed  CAS  Google Scholar 

  222. Holli K, Isola J, Guziek J. Low biologic aggressiveness in women using hormone replacement therapy. J Clin Oncol 1998; 16: 3115–20

    PubMed  CAS  Google Scholar 

  223. Willis DB, Calle EE, Miracle-McMahill HL, et al. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 449–57

    Article  PubMed  CAS  Google Scholar 

  224. Yuen J, Persson I, Bergkvist L, et al. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for ‘healthy drug-user’ effect. Cancer Causes Control 1993; 4: 369–74

    Article  PubMed  CAS  Google Scholar 

  225. Schairer C, Gail M, Bryne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999; 91: 264–70

    Article  PubMed  CAS  Google Scholar 

  226. Beral V, Banks E, Reeves G, et al. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999; 4: 191–210

    PubMed  CAS  Google Scholar 

  227. Ginsburg ES, Walsh BW, Shea BF, et al. Effect of acute ethanol ingestion on prolactin in menopausal women using estradiol replacement. Gynecol Obstet Invest 1995; 39: 47–9

    Article  PubMed  CAS  Google Scholar 

  228. Ginsburg ES, Mello NK, Mendelson JH, et al. Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 1996; 276: 1747–51

    Article  PubMed  CAS  Google Scholar 

  229. Yong LC, Brown CC, Schatezkin A, et al. Prospective study of relative weight and risk of breast cancer: the breast cancer detection demonstration project follow-up study 1979 to 1987–1989. Am J Epidemiol 1996; 143: 985–95

    Article  PubMed  CAS  Google Scholar 

  230. MacDonald PC, Edman CD, Hemsell DC, et al. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978; 130: 448–55

    PubMed  CAS  Google Scholar 

  231. Eng ET, Williams D, Mandava U, et al. Suppression of aromatase (estrogen synthetase) by red wine phytochemicals. Breast Cancer Res Treat 2001; 67: 133–46

    Article  PubMed  CAS  Google Scholar 

  232. Smith-Warner S, Spiegleman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998; 279: 535–40

    Article  PubMed  CAS  Google Scholar 

  233. Burroughs KD, Dunn SE, Barrett C, et al. Insulin-like growth factor-1: a key regulator of human cancer risk? J Natl Cancer Inst 1999; 71: 579–81

    Article  Google Scholar 

  234. Forbes GB, Brown MR, Welle SL, et al. Hormonal response to overfeeding. Am J Clin Nutr 1989; 49: 608–11

    PubMed  CAS  Google Scholar 

  235. Zhang L, Bird RP, Bruce WR. Proliferative activity of murine mammary epithelium as effected by dietary fat and calcium. Cancer Res 1987; 47: 4905–8

    PubMed  CAS  Google Scholar 

  236. Abraham S, Faulkin LJ, Hillyard LA, et al. Effects of dietary fat on tumorigenesis in the mouse mammary gland. J Natl Cancer Instit 1984; 72: 1421–9

    CAS  Google Scholar 

  237. Holmes MD, Hunter DJ, Colditz GA, et al. Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA 1999; 281: 914–20

    Article  PubMed  CAS  Google Scholar 

  238. Prentice RL. Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research. Breast Cancer Res 2000; 2: 268–76

    Article  PubMed  CAS  Google Scholar 

  239. Saez S, Falette N, Guillot C, et al. William L. McGuire memorial symposium: 1,25(OH)2D3 modulation of mammary tumor cell growth in vitro and in vivo. Breast Cancer Res Treat 1993; 27: 69–81

    Article  PubMed  CAS  Google Scholar 

  240. Koike M, Elstner E, Campbell MJ, et al. 19-nor-hexafluoride analogue of vitamin D3: a novel class of potent inhibitors of proliferation of human breast cell lines. Cancer Res 1997; 57: 4545–50

    PubMed  CAS  Google Scholar 

  241. Swami S, Krishnan AV, Feldman D. 1 α,25-dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 2000; 6: 3371–9

    PubMed  CAS  Google Scholar 

  242. Rohan TE, Jain MG, Howe GR, et al. Dietary folate consumption and breast cancer risk. J Natl Cancer Inst 2000; 92: 266–9

    Article  PubMed  CAS  Google Scholar 

  243. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281: 1632–7

    Article  PubMed  CAS  Google Scholar 

  244. Lee HP, Gourley L, Duffy SW, et al. Dietary effects on breast cancer in Singapore. Lancet 1991; 337: 1197–200

    Article  PubMed  CAS  Google Scholar 

  245. Adlecreutz H. Epidemiology of phytoestrogens. Baillieres Clin Endocrinol Metab 1998; 4: 605–23

    Google Scholar 

  246. Hsieh C-Y, Santell RC, Haslam SZ, et al. Estrogenic effects of genistein in the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998; 58: 3833–8

    PubMed  CAS  Google Scholar 

  247. Tou JC, Thompson LV. Exposure to flaxseed or its ligman component during different developmental stages influences rat mammary gland structures. Carcinogenesis 1999; 20: 1831–5

    Article  PubMed  CAS  Google Scholar 

  248. Lu LJ, Anderson KE, Grady JJ, et al. Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Res 2000; 60: 4112–21

    PubMed  CAS  Google Scholar 

  249. Cassidy A, Bingham S, Setchell KD. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 1994; 60: 333–40

    PubMed  CAS  Google Scholar 

  250. Duncan AM, Merz BE, Xu X, et al. Soy isoflavones exert modest hormonal effects in premenopausal women. J Clin Endocrinol Metab 1999; 84: 192–7

    Article  PubMed  CAS  Google Scholar 

  251. Haggans CJ, Hutchins AM, Olson BA, et al. Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer 1999; 33: 188–95

    Article  PubMed  CAS  Google Scholar 

  252. Xu X, Duncan AM, Wangen KE, et al. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9: 781–6

    PubMed  CAS  Google Scholar 

  253. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863–70

    Article  PubMed  CAS  Google Scholar 

  254. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139: 4252–63

    Article  PubMed  CAS  Google Scholar 

  255. Li Y, Bhuiyan M, Sarkar FH. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J Oncol 1999; 15: 525–33

    PubMed  CAS  Google Scholar 

  256. McMichael-Phillips DF, Harding C, Morton M, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal breast. Am J Clin Nutr 1998; 68(6 Suppl): 1431S–5S

    PubMed  CAS  Google Scholar 

  257. van der Leede BJ, Folkers GE, van den Brink CE, et al. Retinoic acid receptor alpha 1 isoform is induced by estradiol and confers retinoic acid sensitivity in human breast cancer cells. Mol Cell Endocrinol 1995; 109: 77–86

    Article  PubMed  Google Scholar 

  258. Nakachi K, Suemasu K, Suga K, et al. Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 1998; 89: 254–61

    Article  PubMed  CAS  Google Scholar 

  259. Mitscher LA, Jung M, Shankel D, et al. Chemoprotection: a review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents. Med Res Rev 1997; 17: 327–65

    Article  PubMed  CAS  Google Scholar 

  260. Nagata C, Kabuto M, Shimizu H. Association of coffee, green tea and caffeine intakes with serum concentrations of estradiol and sex hormone-binding globulin in premenopausal Japanese women. Nutr Cancer 1998; 30: 21–4

    Article  PubMed  CAS  Google Scholar 

  261. Rockhill B, Willett WC, Hunter DJ, et al. A prospective study of recreational physical activity and breast cancer risk. Arch Intern Med 1999; 159: 2290–6

    Article  PubMed  CAS  Google Scholar 

  262. Carpenter CL, Ross RK, Paganini-Hill A, et al. Lifetime exercise activity and breast cancer risk among post-menopausal women. Br J Cancer 1999; 80: 1852–8

    Article  PubMed  CAS  Google Scholar 

  263. Stoll BA. Adiposity as a risk determinant for postmenopausal breast cancer. Int J Obes Relat Metab Disord 2000; 24: 527–33

    Article  PubMed  CAS  Google Scholar 

  264. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371–88

    Article  PubMed  CAS  Google Scholar 

  265. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA 2001; 286: 2251–6

    Article  PubMed  CAS  Google Scholar 

  266. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: the Stockholm breast cancer study group. J Natl Cancer Inst 1993; 85: 1398–406

    Article  PubMed  CAS  Google Scholar 

  267. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial: the Scottish cancer trials breast group. BMJ 1995; 311: 977–80

    Article  PubMed  CAS  Google Scholar 

  268. Reis SE, Costantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. J Natl Cancer Inst 2001; 93: 16–21

    Article  PubMed  CAS  Google Scholar 

  269. Grey AB, Stapleton JP, Evans MC, et al. The effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995; 80: 3191–5

    Article  PubMed  CAS  Google Scholar 

  270. Saarto T, Blomqvist C, Ehnholm C, et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996; 14: 429–33

    PubMed  CAS  Google Scholar 

  271. Shewmon DA, Stock JL, Abusamra LC, et al. Tamoxifen decreases lipoprotein (a) in patients with breast cancer. Metabolism 1994; 43: 531–2.

    Article  PubMed  CAS  Google Scholar 

  272. Anker G, Lonning PE, Ueland PM, et al. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995; 60: 365–8

    Article  PubMed  CAS  Google Scholar 

  273. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptionmetry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78–84

    PubMed  CAS  Google Scholar 

  274. Jordan VC. Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. J Natl Cancer Inst 2001; 93: 2–4

    Article  PubMed  CAS  Google Scholar 

  275. Early breast cancer trialists’ collaborative group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451–67

    Article  Google Scholar 

  276. Jones AL, Powles TJ, Treleaven JG, et al. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer 1992; 66: 744–7

    Article  PubMed  CAS  Google Scholar 

  277. Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level and platelet count change with adjuvant tamoxifen therapy. Arch Int Med 1992; 152: 317–20

    Article  CAS  Google Scholar 

  278. Chang J, Powles TJ, Ashley SE, et al. The effect of tamoxifen and hormone replacement in serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised controlled tamoxifen prevention study. Ann Oncol 1996; 7: 671–5

    Article  PubMed  CAS  Google Scholar 

  279. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998; 90: 1461–7

    Article  PubMed  CAS  Google Scholar 

  280. Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1. J Clin Oncol 1999; 17: 2659–69

    PubMed  CAS  Google Scholar 

  281. Smith TJ, Hillner BE. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. J Clin Oncol 2000; 18: 284–6

    PubMed  CAS  Google Scholar 

  282. Grann VR, Sundararajan V, Jacobson JS, et al. Decision analysis of tamoxifen for the prevention of breast cancer. Cancer J Sci Am 2000; 6: 169–78

    CAS  Google Scholar 

  283. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93–7

    PubMed  CAS  Google Scholar 

  284. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98–101

    PubMed  CAS  Google Scholar 

  285. Guerrieri-Gonzaga A, Galli A, Rotmensz N, et al. The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives. Ann NY Acad Sci 2001; 949: 113–22

    Article  PubMed  CAS  Google Scholar 

  286. Ross PJ, Powles TJ. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials. Clin Breast Cancer 2001; 2: 33–6

    Article  PubMed  CAS  Google Scholar 

  287. Powles TJ. The Royal Marsden Hospital (RMH) trial: key points and remaining questions. Ann NY Acad Sci 2001; 949: 109–12

    Article  PubMed  CAS  Google Scholar 

  288. Osin P, Crook T, Powles T, et al. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet 1998; 351: 1487

    Article  PubMed  CAS  Google Scholar 

  289. Karp SE, Tonin PN, Begin LR, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997; 80: 435–41

    Article  PubMed  CAS  Google Scholar 

  290. Loman N, Johannsson O, Bendahl PO, et al. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998; 83: 310–9

    Article  PubMed  CAS  Google Scholar 

  291. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study: hereditary breast cancer clinical study group. Lancet 2000; 356: 1876–81

    Article  PubMed  CAS  Google Scholar 

  292. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993–2000

    Article  PubMed  CAS  Google Scholar 

  293. Decensi A, Gandini S, Guerrieri-Gonzaga A, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 1999; 17: 2633–8

    PubMed  CAS  Google Scholar 

  294. Jordan JC. Tamoxifen: too much of a good thing? J Clin Oncol 1999; 17: 2629–30

    PubMed  CAS  Google Scholar 

  295. Delmas PD, Bjarnasan NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7

    Article  PubMed  CAS  Google Scholar 

  296. Buzdar AV, Marcus C, Holmes F, et al. Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 1988; 45: 344–5

    Article  PubMed  CAS  Google Scholar 

  297. Gradishar WJ, Glusman JE, Vogel CL, et al. Raloxifene HCl, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer [abstract]. Breast Cancer Res Treat 1997; 46: 53

    Google Scholar 

  298. Ettinger B, Black DM, Mitlak BH. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial: multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 1999; 282: 637–45

    Article  PubMed  CAS  Google Scholar 

  299. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999; 281: 2189–97

    Article  PubMed  CAS  Google Scholar 

  300. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 145–51

    Article  Google Scholar 

  301. Baker VL, Draper M, Paul S, et al. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator in women with regular menstrual cycles. J Clin Endocrinol Metab 1998; 83: 6–13

    Article  PubMed  CAS  Google Scholar 

  302. Labrie F, Labrie C, Belanger A, et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 1999; 69: 51–84

    Article  PubMed  CAS  Google Scholar 

  303. Couillard S, Gutman M, Labrie C, et al. Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res 1998; 58: 60–4

    PubMed  CAS  Google Scholar 

  304. Sato M, Turner CH, Wang TY, et al. LY353381.HC1: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 1998; 287: 1–7

    PubMed  CAS  Google Scholar 

  305. Munster PN, Buzdar A, Dhingra K et al. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol 2001; 19: 2002–9

    PubMed  CAS  Google Scholar 

  306. Llombart-Cussac A, Bellet AM, Guillem-Porta V, et al. Efficacy and safety of two doses of the selective estrogen receptor modulator (Serm) Ly353381 in locally advanced or metastatic breast cancer (LAMBC): a randomized double blind phase 2 study [abstract]. Proc Am Soc Clin Oncol 2000; 19: 157

    Google Scholar 

  307. Fabian CJ, Kimler BF, Anderson J, et al. Phase I biomarker and toxicity evaluation of LY353381 (a 3rd generation selective estrogen receptor modulator, SERM) in breast cancer [abstract]. Proc Am Soc Clin Oncol 2000; 19: 290

    Google Scholar 

  308. Greenberger LM, Annable T, Collins KI, et al. A new anti-estrogen, 2-(4-hydroxy-phenyl) -3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. Clin Cancer Res 2001; 7: 3166–77

    PubMed  CAS  Google Scholar 

  309. Nass SJ, Herman JG, Gabrielson E. Aberrant methylation of the estrogen receptor and E-cadherin 5’ CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000; 60: 4346–8

    PubMed  CAS  Google Scholar 

  310. Speirs V, Parkes AT, Kerin MJ, et al. Coexpression of estrogen receptor α and β: poor prognostic factors in human breast cancer? Cancer Res 1999; 59: 525–8

    PubMed  CAS  Google Scholar 

  311. Fujimoto N, Katzenellenbogen BS. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. Mol Endocrinol 1994; 8: 296–304

    Article  PubMed  CAS  Google Scholar 

  312. Takimoto GS, Graham JD, Jackson TA, et al. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol 1999; 69: 45–50

    Article  PubMed  CAS  Google Scholar 

  313. Spencer TE, Jenster G, Burcin MM, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997; 389: 194–8

    Article  PubMed  CAS  Google Scholar 

  314. Lavinsky RM, Jepsen K, Heinzel T, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 1998; 95: 2920–5

    Article  PubMed  CAS  Google Scholar 

  315. Stoica A, Saceda M, Doraiswamy VL, et al. Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. J Endocrinol 2000; 165: 371–8

    Article  PubMed  CAS  Google Scholar 

  316. Hopp TA, Hilsenbeck S, Mohsin S, et al. A hypersensitive estrogen receptor α protein in premalignant breast lesions [abstract]. Breast Cancer Res Treat 2000; 64: 33

    Google Scholar 

  317. van der Flier S, Brinkman A, Look MP, et al. BCAR1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 2000; 92: 120–7

    Article  PubMed  Google Scholar 

  318. Jordan VC. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 1995; 35: 195–211

    Article  PubMed  CAS  Google Scholar 

  319. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature 1998; 19: 187–91

    CAS  Google Scholar 

  320. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation of histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature 1999; 21: 103–7

    CAS  Google Scholar 

  321. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 28: 386–9

    Google Scholar 

  322. Dotzlaw H, Leygue E, Watson PH, et al. Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 1997; 82: 2371–4

    Article  PubMed  CAS  Google Scholar 

  323. Katzenellenbogen BS, Montano MM, Ekena K, et al. William L. McGuire memorial lecture: antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 1997; 44: 23–38

    Article  PubMed  CAS  Google Scholar 

  324. Webb P, Lopez GN, Uht RM, et al. Tamoxifen activation of the estrogen receptor AP-1 pathway: potential origin for the cell-specific estrogen like effects of anti-estrogens. Mol Endocrinol 1995; 9: 443–56

    Article  PubMed  CAS  Google Scholar 

  325. Enmark E, Gustafsson JA. Estrogen receptor β — a novel receptor opens up new possibilities for cancer diagnosis and treatment. Endocr Relat Cancer 1998; 5: 213–22

    Article  CAS  Google Scholar 

  326. Horwitz KB, Jackson TA, Bain DL, et al. Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996; 10: 1167–77

    Article  PubMed  CAS  Google Scholar 

  327. Dumont JA, Bitonti AJ, Wallace CD, et al. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 1996; 7: 351–9

    PubMed  CAS  Google Scholar 

  328. Chan KC, Knox WF, Gandhi A, et al. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg 2001; 88: 412–8

    Article  PubMed  CAS  Google Scholar 

  329. Osborne CK. A double-blind randomized trial comparing the efficacy and tolerability of Faslodex™ (fulvestrant) with Arimidex™ in postmenopausal women with advanced breast cancer [abstract]. Breast Cancer Res Treat 2000; 64: 27

    Google Scholar 

  330. Howell A, DeFriend DJ, Robertson JF, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996; 74: 300–8

    Article  PubMed  CAS  Google Scholar 

  331. Howell T. New endocrine agents. Cancer Treat Rev 1997; 23(1 Suppl): S49–57

    Article  PubMed  CAS  Google Scholar 

  332. Howell A, Robertson JRR, Quaresma Albano J, et al. Comparison of efficacy and tolerability of fulvestrant (Faslodex™) with anastrazole (Arimidex™) in postmenopausal women with advanced breast cancer (LABC preliminary results) [abstract]. Breast Cancer Res Treat 2000; 64: 27

    Google Scholar 

  333. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60: 4152–60

    PubMed  CAS  Google Scholar 

  334. Robertson JFR, Dixon M, Bimdred N, et al. A partially-blind, randomised, multicentre study comparing the anti-tumor effects of single doses (50, 125, and 250 mg) of long-acting (LA) ‘faslodex’ (ICI 182,780) with tamoxifen in postmenopausal women with primary breast cancer prior to surgery [abstract]. Breast Cancer Res Treat 1999; 57: 31

    Google Scholar 

  335. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596–606

    PubMed  CAS  Google Scholar 

  336. Dixon JM, Love CDB, Renshaw L, et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 1999; 6: 227–30

    Article  PubMed  CAS  Google Scholar 

  337. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifenas first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18: 3748–57

    PubMed  CAS  Google Scholar 

  338. Harper-Wynne CL, Ross GM, Sacks NP, et al. Study of the biological effects of the aromatase inhibitor letrozole in healthy postmenopausal women: rationale for prevention [abstract]. Breast Cancer Res Treat 2000; 64: 47

    Google Scholar 

  339. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18: 3758–67

    PubMed  CAS  Google Scholar 

  340. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808–16

    PubMed  CAS  Google Scholar 

  341. Baum M, on behalf of the ATAC Trialists’ Group: The ATAC (Arimidex, Tamoxifen, Alone, or in Combination) adjuvant breast cancer trial in post-menopausal (PM) women [abstract]. Breast Cancer Res Treatment 2001; 69: 210

    Google Scholar 

  342. Purohit A, Hejaz HA, Woo LW, et al. Recent advances in the development of steroid sulphatase inhibitors. J Steroid Biochem Mol Biol 1999; 69: 227–38

    Article  PubMed  CAS  Google Scholar 

  343. Prost-Avallet O, Oursin J, Adessi GL. In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma. J Steroid Biochem Mol Biol 1991; 39: 967–73

    Article  PubMed  CAS  Google Scholar 

  344. Santner SJ, Santen RJ. Inhibition of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase by antiestrogens. J Steroid Biochem Mol Biol 1993; 45: 383–90

    Article  PubMed  CAS  Google Scholar 

  345. Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997; 17: 135–40

    PubMed  CAS  Google Scholar 

  346. Chetrite GS, Kloosterboer HJ, Philippe JC, et al. Effect of Org OD14 (LIVIAL) and its metabolites on human estrogen sulphotransferase activity inthe hormone-dependent MCF-7 and T-47D, and the hormone-independent MDA-MB-231, breast cancer cell lines. Anticancer Res 1999; 19: 269–75

    PubMed  CAS  Google Scholar 

  347. Gottardis MM, Bischoff ED, Shirley MA, et al. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996; 56: 5566–70

    PubMed  CAS  Google Scholar 

  348. Schneider SM, Offterdinger M, Huber H, et al. Involvement of nuclear steroid/thyroid/retinoid receptors and of protein kinases in the regulation of growth and of c-erbB and retinoic acid receptor expression in MCF-7 breast cancer cells. Breast Cancer Res Treat 1999; 58: 171–81

    Article  PubMed  CAS  Google Scholar 

  349. Xu XC, Sneige N, Liu X, et al. Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res 1997; 15: 4992–6

    Google Scholar 

  350. Liu Y, Lee MO, Wang HG, et al. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 1996; 16: 1138–49

    PubMed  CAS  Google Scholar 

  351. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy [editorial]. J Natl Cancer Inst 1995; 87: 1655–7

    Article  PubMed  CAS  Google Scholar 

  352. Torrisi R, Pensa F, Antonietta M, et al. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 1993; 53: 4769–71

    PubMed  CAS  Google Scholar 

  353. Mariani L, Formelli F, De Palo G, et al. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability. Tumori 1996; 82: 444–9

    PubMed  CAS  Google Scholar 

  354. Veronesi U, DePalo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999; 91: 1847–56

    Article  PubMed  CAS  Google Scholar 

  355. Conley B, O’Shaughnessy J, Prindiville S, et al. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydr-oxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 2000; 18: 275–83

    PubMed  CAS  Google Scholar 

  356. Cobleigh MA, Gray R, Graham M, et al. Fenretinide (FEN) vs placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group phase III intergroup trial (EB193, INT-0151) [abstract]. Proc Am Soc Clin Oncol 2000; 19: 328

    Google Scholar 

  357. Bischoff ED, Heyman RA, Lamph WW. Effect of retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 1999; 91: 2118–23

    Article  PubMed  CAS  Google Scholar 

  358. Sporn MB. Retinoids and demethylating agents: looking for partners. J Natl Cancer Inst 2000; 92: 780–1

    Article  PubMed  CAS  Google Scholar 

  359. Leveque J, Foucher F, Bansard JY, et al. Polyamine profiles in tumor, normal tissue of the homologous breast, blood, and urine of breast cancer sufferers. Breast Cancer Res Treat 2000; 60: 99–105

    Article  PubMed  CAS  Google Scholar 

  360. Gould MN. Prevention and therapy of mammary cancer by monoterpenes. J Cell Biochem Suppl 1995; 22: 139–44

    Article  PubMed  CAS  Google Scholar 

  361. Ripple GH; Gould MN; Stewart JA;, et al. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 1998; 4: 1159–64

    PubMed  CAS  Google Scholar 

  362. Mehta RR, Bratescu L, Graves JM, et al. Differentiation of human breast carcinoma cells by a novel vitamin D analog: 1al-pha-hydroxyvitamin D5. Int J Oncol 2000; 16: 65–73

    PubMed  CAS  Google Scholar 

  363. Vink-van Wijingaarden T, Pols HAP, Buurman CJ, et al. Inhibition of insulin and insulin-like growth factor-1-stimulated growth of human breast cancer cells by 1, 25 dihydroxy-vitamin D3 and the vitamin D3 analogue EB 1089. Eur J Cancer 1996; 32A: 842–8

    Article  Google Scholar 

  364. Rozen F, Yang XF, Huynh H, et al. Antiproliferative action of vitamin D related compounds and insulin-like growth factor binding protein-5 accumulation. J Natl Cancer Inst 1997; 59: 652–6

    Article  Google Scholar 

  365. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996; 56: 5125–7

    PubMed  CAS  Google Scholar 

  366. Harris RE, Alshafie GA, Hussen AI, et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101–3

    PubMed  CAS  Google Scholar 

  367. Tan-Chiu E, Costantino J, Wang J, et al. The effect of tamoxifen on benign breast disease. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT) [abstract]. Breast Cancer Res Treatment 2001; 69: 210

    Google Scholar 

  368. Mendelsohn ME, Karas RH. Protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801–11

    Article  PubMed  CAS  Google Scholar 

  369. Speroff L, Rowan J, Symons J, et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study): a randomized controlled trial. JAMA 1996; 276: 1397–403

    Article  PubMed  CAS  Google Scholar 

  370. Mosca L. Estrogen and atherosclerosis. J Invest Med 1998; 46: 381–6

    CAS  Google Scholar 

  371. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835–42

    Article  PubMed  CAS  Google Scholar 

  372. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. Arandomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939–53

    PubMed  CAS  Google Scholar 

  373. Wiseman LR, McTavish D. Transdermal estradiol/norethister-one: a review of its pharmacologic properties and clinical use in postmenopausal women. Drugs Aging 1994; 4: 238–56

    Article  PubMed  CAS  Google Scholar 

  374. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in use of hormone replacement therapy. Lancet 1996; 348: 977–80

    Article  PubMed  CAS  Google Scholar 

  375. Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 1997; 278: 477

    Article  PubMed  CAS  Google Scholar 

  376. Kessel B. Alternatives to estrogen for menopausal women. Proc Soc Exp Biol Med 1998; 217: 38–44

    PubMed  CAS  Google Scholar 

  377. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983–7

    Article  PubMed  CAS  Google Scholar 

  378. Herbert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 1998; 7: 653–9

    Google Scholar 

  379. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999; 20: 279–307

    Article  PubMed  CAS  Google Scholar 

  380. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in post-menopausal women: effects on cognitive function and dementia. JAMA 1998; 279: 688–95

    Article  PubMed  CAS  Google Scholar 

  381. Rice MM, Graves AB, McCurry SM, et al. Estrogen replacement therapy and cognitive function in women without dementia. Am J Med 1997; 103(3A): 26S–35S

    Article  PubMed  CAS  Google Scholar 

  382. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001; 344: 1207–13

    Article  PubMed  CAS  Google Scholar 

  383. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000; 64: 165–76

    Article  PubMed  CAS  Google Scholar 

  384. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age: early postmenopausal intervention cohort study group. N Eng J Med 1998; 338: 485–92

    Article  CAS  Google Scholar 

  385. Heaney RP, Draper MW. Raloxifene and estrogen comparative bone-remodeling kinetics. J Clin Endocrinol Metab 1997; 82: 3425–9

    Article  PubMed  CAS  Google Scholar 

  386. Persson I, Yuen J, Bergkvist L, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327–32

    Article  PubMed  CAS  Google Scholar 

  387. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527–37

    Article  PubMed  CAS  Google Scholar 

  388. Rodriguez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285: 1460–5

    Article  PubMed  CAS  Google Scholar 

  389. Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130: 545–53

    PubMed  CAS  Google Scholar 

  390. Matthews KA, Kuller LH, Wing RR, et al. Prior to estrogen replacement therapy, are users healthier than non users? Am J Epidemiol 1996; 143: 971–8

    Article  PubMed  CAS  Google Scholar 

  391. McNagny SE, Wenger NK, Frank E. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States. Ann Intern Med 1997; 127: 1093–6

    PubMed  CAS  Google Scholar 

  392. McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Int Med 1999; 131: 605–16

    PubMed  CAS  Google Scholar 

  393. Bergkvist L, Adami H-O, Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989; 130: 221–8

    PubMed  CAS  Google Scholar 

  394. Magnusson C, Holmberg L, Noden T, et al. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996; 38: 325–34

    Article  PubMed  CAS  Google Scholar 

  395. Cobleigh MA, Norlock FE, Oleske DM, et al. Hormone replacement therapy and high S phase in breast cancer. JAMA 1999; 281: 1528–30

    Article  PubMed  CAS  Google Scholar 

  396. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77–84

    Article  PubMed  CAS  Google Scholar 

  397. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633–7

    Article  PubMed  CAS  Google Scholar 

  398. Pritchard K